{"disease":{"id":"nyha-class-iii-iv-heart-failure-with-reduced-ejection-fraction","name":"NYHA Class III-IV heart failure with reduced ejection fraction","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"aldactone","indication_name":"NYHA Class III-IV heart failure with reduced ejection fraction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03387813","title":"Hemodynamic-GUIDEd Management of Heart Failure","phase":"NA","overall_status":"COMPLETED","enrollment_count":2358,"lead_sponsor_name":"Abbott Medical Devices","has_results":true},{"nct_id":"NCT06299176","title":"Whole Heart Radiotherapy for End-stage Heart Failure","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":6,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false}],"total":2},"guidelines":[{"drug_id":"aldactone","guideline_body":"FDA label","recommendation":"Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies.","line_of_therapy":"adjuvant","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}